A new dosing regimen for Turalio (pexidartinib) is available for the treatment of adults with symptomatic tenosynovial giant cell tumor.
In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.
Rolvedon is a novel, long-acting granulocyte colony-stimulating factor comprised of 2 protein components, an analogue of G-CSF and an Fc antibody fragment.
The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
The approval was based on data from the phase 2 MOUNTAINEER trial, which included patients with HER2-positive unresectable or metastatic colorectal cancer.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
In preclinical studies, WP1122 has shown to increase cellular uptake of 2-DG, increase drug half-life, and increase the ability to cross the blood brain barrier.
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
The approval was based on data from the phase 3 ELUCIDATE study.
